Skip to content
What if…

The small intestine functions as a control center for the entire immune system?

It turns out…

We can identify specific single clonal strains of microbes that target and engage with immune cells in the small intestine to direct systemic immune responses for the treatment of cancer, inflammatory diseases and beyond.

Founded by Flagship Pioneering in 2015, Evelo Biosciences (NASDAQ: EVLO) is a clinical-stage biotechnology company developing monoclonal microbials, a new modality of medicines. Evelo’s product candidates are orally-delivered, single strains of microbes, selected for defined pharmacological properties. They are developed to engage immune cells in the small intestine and drive changes in systemic biology. Evelo believes that monoclonal microbials have the potential to be broadly applicable across many diseases including immunoinflammatory, cancer, autoimmune, metabolic, and neuroinflammatory diseases.

Latest Press from Evelo Biosciences

Next